594 related articles for article (PubMed ID: 31430204)
1. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α and HIF-2α are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation.
Liu Y; Ma Z; Zhao C; Wang Y; Wu G; Xiao J; McClain CJ; Li X; Feng W
Toxicol Lett; 2014 Apr; 226(2):117-23. PubMed ID: 24503013
[TBL] [Abstract][Full Text] [Related]
3. The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis.
Wang H; Wang L; Li Y; Luo S; Ye J; Lu Z; Li X; Lu H
Biomed Pharmacother; 2021 Aug; 140():111778. PubMed ID: 34062416
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
5. Hepatic hypoxia-inducible factors inhibit PPARα expression to exacerbate acetaminophen induced oxidative stress and hepatotoxicity.
Li D; Du Y; Yuan X; Han X; Dong Z; Chen X; Wu H; Zhang J; Xu L; Han C; Zhang M; Xia Q
Free Radic Biol Med; 2017 Sep; 110():102-116. PubMed ID: 28583670
[TBL] [Abstract][Full Text] [Related]
6. Silencing HIF-1α aggravates non-alcoholic fatty liver disease in vitro through inhibiting PPAR-α/ANGPTL4 singling pathway.
He Y; Yang W; Gan L; Liu S; Ni Q; Bi Y; Han T; Liu Q; Chen H; Hu Y; Long Y; Yang L
Gastroenterol Hepatol; 2021 May; 44(5):355-365. PubMed ID: 33272734
[TBL] [Abstract][Full Text] [Related]
7. Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α.
Yu L; Wang H; Han X; Liu H; Zhu D; Feng W; Wu J; Bi Y
J Endocrinol; 2020 Jul; 246(1):57-67. PubMed ID: 32369776
[TBL] [Abstract][Full Text] [Related]
8. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
[TBL] [Abstract][Full Text] [Related]
9. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
10. HIF-1-dependent lipin1 induction prevents excessive lipid accumulation in choline-deficient diet-induced fatty liver.
Arai T; Tanaka M; Goda N
Sci Rep; 2018 Sep; 8(1):14230. PubMed ID: 30242180
[TBL] [Abstract][Full Text] [Related]
11. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
12. FMO1 Promotes Nonalcoholic Fatty Liver Disease Progression by Regulating PPARα Activation and Inducing Ferroptosis.
Zou L; Shi Q; Li Y; Yuan Z; Peng L; Lu J; Zhu H; Ma J
Discov Med; 2023 Aug; 35(177):612-622. PubMed ID: 37553313
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein.
Morello E; Sutti S; Foglia B; Novo E; Cannito S; Bocca C; Rajsky M; Bruzzì S; Abate ML; Rosso C; Bozzola C; David E; Bugianesi E; Albano E; Parola M
Hepatology; 2018 Jun; 67(6):2196-2214. PubMed ID: 29266399
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia induces dysregulation of lipid metabolism in HepG2 cells via activation of HIF-2α.
Cao R; Zhao X; Li S; Zhou H; Chen W; Ren L; Zhou X; Zhang H; Shi R
Cell Physiol Biochem; 2014; 34(5):1427-41. PubMed ID: 25323790
[TBL] [Abstract][Full Text] [Related]
15. Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis.
Li B; Zhang Z; Zhang H; Quan K; Lu Y; Cai D; Ning G
J Mol Endocrinol; 2014 Dec; 53(3):393-403. PubMed ID: 25312970
[TBL] [Abstract][Full Text] [Related]
16. Activation of the Hypoxia Inducible Factor 1α Subunit Pathway in Steatotic Liver Contributes to Formation of Cholesterol Gallstones.
Asai Y; Yamada T; Tsukita S; Takahashi K; Maekawa M; Honma M; Ikeda M; Murakami K; Munakata Y; Shirai Y; Kodama S; Sugisawa T; Chiba Y; Kondo Y; Kaneko K; Uno K; Sawada S; Imai J; Nakamura Y; Yamaguchi H; Tanaka K; Sasano H; Mano N; Ueno Y; Shimosegawa T; Katagiri H
Gastroenterology; 2017 May; 152(6):1521-1535.e8. PubMed ID: 28088462
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver.
Mooli RGR; Rodriguez J; Takahashi S; Solanki S; Gonzalez FJ; Ramakrishnan SK; Shah YM
Cell Mol Gastroenterol Hepatol; 2021; 12(2):585-597. PubMed ID: 33798787
[TBL] [Abstract][Full Text] [Related]
18. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
Wang X; Wang J; Ying C; Xing Y; Su X; Men K
BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
[TBL] [Abstract][Full Text] [Related]
20. Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles.
Hernández A; Geng Y; Sepúlveda R; Solís N; Torres J; Arab JP; Barrera F; Cabrera D; Moshage H; Arrese M
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165753. PubMed ID: 32126269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
